There was no evidence that the weight reducing effect of bupropion was dose-dependent.

Long-term treatment with bupropion SR may reduce or delay smoking relapse.

Larger randomized, controlled trials of bupropion for ST users are needed.

Under paroxetine, ratings of subjective sexual dysfunction increased compared with placebo or bupropion.

Unlike other antidepressants, bupropion may increase or intensify REM sleep.

Preclinical and clinical studies of bupropion and naltrexone alone and in combination are reviewed.

Depression symptoms did not mediate the effects of bupropion on abstinence at either time point.

Patients' doses were titrated to a maximum fixed daily dose of 300 mg of bupropion.

Randomized controlled clinical trials have shown that bupropion SR doubles abstinence rates compared with placebo.

Two hundred and fifty-one smokers received 10-week treatment with bupropion or placebo, plus behavioral counseling.

Both topiramate and bupropion SR were generally well tolerated.

In a path model, change in NA was a significant mediator of bupropion's effects on cessation.

But what they soon realized was that bupropion was functioning as a kind of nicotine substitute.

We investigated the neural bases of paroxetine-related subjective sexual dysfunction when compared with bupropion and placebo.

A number of recent studies indicate that bupropion can facilitate reduced tobacco smoking among patients with schizophrenia.

Further studies, with longer durations of bupropion treatment and more subjects, are needed to confirm these findings.